AU8362598A - New formulation - Google Patents

New formulation Download PDF

Info

Publication number
AU8362598A
AU8362598A AU83625/98A AU8362598A AU8362598A AU 8362598 A AU8362598 A AU 8362598A AU 83625/98 A AU83625/98 A AU 83625/98A AU 8362598 A AU8362598 A AU 8362598A AU 8362598 A AU8362598 A AU 8362598A
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition according
drying
compound
independently represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU83625/98A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra Pharmaceuticals Ltd
Astra Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU8362598(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Pharmaceuticals Ltd, Astra Pharmaceutical Products Inc filed Critical Astra Pharmaceuticals Ltd
Publication of AU8362598A publication Critical patent/AU8362598A/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Alteration of Name(s) of Applicant(s) under S113 Assignors: ASTRA PHARMACEUTICALS LIMITED
Priority to AU2003257524A priority Critical patent/AU2003257524B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU83625/98A 1997-07-11 1998-06-29 New formulation Abandoned AU8362598A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003257524A AU2003257524B2 (en) 1997-07-11 2003-10-23 New formulation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702680 1997-07-11
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003257524A Division AU2003257524B2 (en) 1997-07-11 2003-10-23 New formulation

Publications (1)

Publication Number Publication Date
AU8362598A true AU8362598A (en) 1999-02-08

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
AU83625/98A Abandoned AU8362598A (en) 1997-07-11 1998-06-29 New formulation

Country Status (35)

Country Link
US (1) US6130208A (cg-RX-API-DMAC10.html)
EP (1) EP1000079B1 (cg-RX-API-DMAC10.html)
JP (1) JP4950380B2 (cg-RX-API-DMAC10.html)
KR (1) KR100786654B1 (cg-RX-API-DMAC10.html)
CN (2) CN1864696A (cg-RX-API-DMAC10.html)
AR (1) AR013157A1 (cg-RX-API-DMAC10.html)
AT (1) ATE340801T1 (cg-RX-API-DMAC10.html)
AU (1) AU8362598A (cg-RX-API-DMAC10.html)
BR (1) BR9810703A (cg-RX-API-DMAC10.html)
CA (1) CA2295628C (cg-RX-API-DMAC10.html)
CY (1) CY1105805T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ298110B6 (cg-RX-API-DMAC10.html)
DE (1) DE69836023T2 (cg-RX-API-DMAC10.html)
DK (1) DK1000079T3 (cg-RX-API-DMAC10.html)
EE (1) EE04119B1 (cg-RX-API-DMAC10.html)
ES (1) ES2273425T3 (cg-RX-API-DMAC10.html)
HU (1) HU226489B1 (cg-RX-API-DMAC10.html)
ID (1) ID24716A (cg-RX-API-DMAC10.html)
IL (2) IL133868A0 (cg-RX-API-DMAC10.html)
IS (1) IS2439B (cg-RX-API-DMAC10.html)
MY (1) MY116421A (cg-RX-API-DMAC10.html)
NO (1) NO329918B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ502073A (cg-RX-API-DMAC10.html)
PL (1) PL192768B1 (cg-RX-API-DMAC10.html)
PT (1) PT1000079E (cg-RX-API-DMAC10.html)
RU (1) RU2216330C2 (cg-RX-API-DMAC10.html)
SA (1) SA98190328B1 (cg-RX-API-DMAC10.html)
SE (1) SE9702680D0 (cg-RX-API-DMAC10.html)
SI (1) SI1000079T1 (cg-RX-API-DMAC10.html)
SK (1) SK285766B6 (cg-RX-API-DMAC10.html)
TR (1) TR200000006T2 (cg-RX-API-DMAC10.html)
TW (1) TW585764B (cg-RX-API-DMAC10.html)
UA (1) UA65576C2 (cg-RX-API-DMAC10.html)
WO (1) WO1999002542A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA985669B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038647A1 (ja) * 2004-10-05 2006-04-13 Asahi Kasei Pharma Corporation 補酵素の安定化方法およびその組成物
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 ３−（ビアリールオキシ）プロピオン酸誘導体
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2498731B1 (en) 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
WO2012079035A1 (en) * 2010-12-10 2012-06-14 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
DK2744424T3 (en) 2011-08-17 2018-01-22 Samuel Shiber Adaptively rotating catheter to open clogged vessels in the body
EP3978002A1 (en) 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
PE20221170A1 (es) 2015-01-14 2022-07-25 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
ES3067885T3 (en) 2017-06-23 2026-05-26 Chiesi Farm Spa Cangrelor for the treatment and/or prevention of shunt or stent thrombosis
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (cg-RX-API-DMAC10.html) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DE69406649T2 (de) * 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge
CZ306394A3 (en) * 1993-12-14 1995-08-16 Lilly Co Eli Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
WO1996040265A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku

Also Published As

Publication number Publication date
DK1000079T3 (da) 2006-11-20
SE9702680D0 (sv) 1997-07-11
TR200000006T2 (tr) 2000-07-21
CA2295628C (en) 2008-07-29
DE69836023T2 (de) 2007-04-12
SK285766B6 (sk) 2007-07-06
UA65576C2 (uk) 2004-04-15
ATE340801T1 (de) 2006-10-15
CZ200083A3 (cs) 2000-06-14
HK1026429A1 (en) 2000-12-15
AR013157A1 (es) 2000-12-13
HUP0002622A3 (en) 2002-04-29
EE200000022A (et) 2000-10-16
IS5331A (is) 1999-12-30
KR100786654B1 (ko) 2007-12-21
TW585764B (en) 2004-05-01
IL133868A (en) 2010-05-17
RU2216330C2 (ru) 2003-11-20
KR20010021647A (ko) 2001-03-15
EP1000079B1 (en) 2006-09-27
WO1999002542A1 (en) 1999-01-21
EE04119B1 (et) 2003-08-15
PL192768B1 (pl) 2006-12-29
CA2295628A1 (en) 1999-01-21
US6130208A (en) 2000-10-10
SK183699A3 (en) 2000-07-11
EP1000079A1 (en) 2000-05-17
IL133868A0 (en) 2001-04-30
NZ502073A (en) 2001-09-28
MY116421A (en) 2004-01-31
CN1263533A (zh) 2000-08-16
CY1105805T1 (el) 2011-02-02
SA98190328B1 (ar) 2006-08-15
PL337970A1 (en) 2000-09-11
NO20000123L (no) 2000-03-03
BR9810703A (pt) 2000-08-08
HU226489B1 (en) 2009-03-02
JP4950380B2 (ja) 2012-06-13
NO329918B1 (no) 2011-01-24
ES2273425T3 (es) 2007-05-01
JP2001509512A (ja) 2001-07-24
ID24716A (id) 2000-08-03
NO20000123D0 (no) 2000-01-10
CN1864696A (zh) 2006-11-22
ZA985669B (en) 1999-01-11
HUP0002622A2 (hu) 2001-05-28
CZ298110B6 (cs) 2007-06-27
DE69836023D1 (de) 2006-11-09
PT1000079E (pt) 2006-12-29
SI1000079T1 (sl) 2007-08-31
IS2439B (is) 2008-11-15

Similar Documents

Publication Publication Date Title
CA2295628C (en) Stable formulations comprising a nucleotide and a freeze drying additive
AU758857B2 (en) Pharmaceutical compositions for freeze drying
CZ271894A3 (en) Lyophilized preparation containing 1,1,1-phosphinothioylidintrisaziridine and process for preparing thereof
AU2003257524B2 (en) New formulation
HK1026429B (en) New formulation
MXPA00000100A (en) New formulation
MXPA99005664A (en) Pharmaceutical compositions for freeze drying
HK1026366B (en) Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ASTRAZENECA AB

Free format text: THE FORMER OWNER WAS: ASTRA PHARMACEUTICALS LTD.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted